Direct medical costs associated with Parkinson's disease

A population-based study

Cynthia L. Leibson, Kirsten Hall Long, Demetrius M. Maraganore, James Howard Bower, Jeanine E. Ransom, Peter C. O'Brien, A. Walter Rocca

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The objective was to provide population-based estimates of incremental medical costs associated with Parkinson's disease (PD) from onset forward. All Olmsted County, Minnesota, residents with confirmed PD onset from 1987 through 1995 (n = 92) and one age- and sex-matched non-PD referent subject per case were identified with retrospective record review and followed in provider-linked billing data for direct medical costs (excluding outpatient pharmaceutical costs) from 1 year before index (i.e., year of symptom onset) through 10 years after index. Costs for each referent subject were subtracted from those for his/her matched case. Tests for statistical significance used Wilcoxon signed ranks. Preindex costs were similar [median difference in annual costs (MD) = -$3; P = 0.59). One year post index, PD subjects exhibited borderline significantly higher costs compared to referent subjects (MD = $581; P = 0.052); the difference diminished over 5 years (MD = $118; P = 0.82). By 5 to 10 years, however, PD subjects exhibited significantly higher costs (MD = $1,146; P = 0.01). Over the full 10 years, excess costs were concentrated among PD subjects without rest tremor (MD = $2,261, P < 0.01, for those without tremor and -$229, P = 0.99, for those with tremor). These population-based estimates of PD-associated direct medical costs from onset forward can uniquely inform policy decisions and cost-effectiveness research.

Original languageEnglish (US)
Pages (from-to)1864-1871
Number of pages8
JournalMovement Disorders
Volume21
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Parkinson Disease
Costs and Cost Analysis
Population
Tremor
Cost-Benefit Analysis
Outpatients
Research
Pharmaceutical Preparations

Keywords

  • Cost
  • Cost analysis
  • Parkinson's disease
  • Parkinsonian disorders
  • Utilization

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Leibson, C. L., Hall Long, K., Maraganore, D. M., Bower, J. H., Ransom, J. E., O'Brien, P. C., & Rocca, A. W. (2006). Direct medical costs associated with Parkinson's disease: A population-based study. Movement Disorders, 21(11), 1864-1871. https://doi.org/10.1002/mds.21075

Direct medical costs associated with Parkinson's disease : A population-based study. / Leibson, Cynthia L.; Hall Long, Kirsten; Maraganore, Demetrius M.; Bower, James Howard; Ransom, Jeanine E.; O'Brien, Peter C.; Rocca, A. Walter.

In: Movement Disorders, Vol. 21, No. 11, 11.2006, p. 1864-1871.

Research output: Contribution to journalArticle

Leibson, CL, Hall Long, K, Maraganore, DM, Bower, JH, Ransom, JE, O'Brien, PC & Rocca, AW 2006, 'Direct medical costs associated with Parkinson's disease: A population-based study', Movement Disorders, vol. 21, no. 11, pp. 1864-1871. https://doi.org/10.1002/mds.21075
Leibson CL, Hall Long K, Maraganore DM, Bower JH, Ransom JE, O'Brien PC et al. Direct medical costs associated with Parkinson's disease: A population-based study. Movement Disorders. 2006 Nov;21(11):1864-1871. https://doi.org/10.1002/mds.21075
Leibson, Cynthia L. ; Hall Long, Kirsten ; Maraganore, Demetrius M. ; Bower, James Howard ; Ransom, Jeanine E. ; O'Brien, Peter C. ; Rocca, A. Walter. / Direct medical costs associated with Parkinson's disease : A population-based study. In: Movement Disorders. 2006 ; Vol. 21, No. 11. pp. 1864-1871.
@article{303560c75aaf4e12b6591dee7e0a5f73,
title = "Direct medical costs associated with Parkinson's disease: A population-based study",
abstract = "The objective was to provide population-based estimates of incremental medical costs associated with Parkinson's disease (PD) from onset forward. All Olmsted County, Minnesota, residents with confirmed PD onset from 1987 through 1995 (n = 92) and one age- and sex-matched non-PD referent subject per case were identified with retrospective record review and followed in provider-linked billing data for direct medical costs (excluding outpatient pharmaceutical costs) from 1 year before index (i.e., year of symptom onset) through 10 years after index. Costs for each referent subject were subtracted from those for his/her matched case. Tests for statistical significance used Wilcoxon signed ranks. Preindex costs were similar [median difference in annual costs (MD) = -$3; P = 0.59). One year post index, PD subjects exhibited borderline significantly higher costs compared to referent subjects (MD = $581; P = 0.052); the difference diminished over 5 years (MD = $118; P = 0.82). By 5 to 10 years, however, PD subjects exhibited significantly higher costs (MD = $1,146; P = 0.01). Over the full 10 years, excess costs were concentrated among PD subjects without rest tremor (MD = $2,261, P < 0.01, for those without tremor and -$229, P = 0.99, for those with tremor). These population-based estimates of PD-associated direct medical costs from onset forward can uniquely inform policy decisions and cost-effectiveness research.",
keywords = "Cost, Cost analysis, Parkinson's disease, Parkinsonian disorders, Utilization",
author = "Leibson, {Cynthia L.} and {Hall Long}, Kirsten and Maraganore, {Demetrius M.} and Bower, {James Howard} and Ransom, {Jeanine E.} and O'Brien, {Peter C.} and Rocca, {A. Walter}",
year = "2006",
month = "11",
doi = "10.1002/mds.21075",
language = "English (US)",
volume = "21",
pages = "1864--1871",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Direct medical costs associated with Parkinson's disease

T2 - A population-based study

AU - Leibson, Cynthia L.

AU - Hall Long, Kirsten

AU - Maraganore, Demetrius M.

AU - Bower, James Howard

AU - Ransom, Jeanine E.

AU - O'Brien, Peter C.

AU - Rocca, A. Walter

PY - 2006/11

Y1 - 2006/11

N2 - The objective was to provide population-based estimates of incremental medical costs associated with Parkinson's disease (PD) from onset forward. All Olmsted County, Minnesota, residents with confirmed PD onset from 1987 through 1995 (n = 92) and one age- and sex-matched non-PD referent subject per case were identified with retrospective record review and followed in provider-linked billing data for direct medical costs (excluding outpatient pharmaceutical costs) from 1 year before index (i.e., year of symptom onset) through 10 years after index. Costs for each referent subject were subtracted from those for his/her matched case. Tests for statistical significance used Wilcoxon signed ranks. Preindex costs were similar [median difference in annual costs (MD) = -$3; P = 0.59). One year post index, PD subjects exhibited borderline significantly higher costs compared to referent subjects (MD = $581; P = 0.052); the difference diminished over 5 years (MD = $118; P = 0.82). By 5 to 10 years, however, PD subjects exhibited significantly higher costs (MD = $1,146; P = 0.01). Over the full 10 years, excess costs were concentrated among PD subjects without rest tremor (MD = $2,261, P < 0.01, for those without tremor and -$229, P = 0.99, for those with tremor). These population-based estimates of PD-associated direct medical costs from onset forward can uniquely inform policy decisions and cost-effectiveness research.

AB - The objective was to provide population-based estimates of incremental medical costs associated with Parkinson's disease (PD) from onset forward. All Olmsted County, Minnesota, residents with confirmed PD onset from 1987 through 1995 (n = 92) and one age- and sex-matched non-PD referent subject per case were identified with retrospective record review and followed in provider-linked billing data for direct medical costs (excluding outpatient pharmaceutical costs) from 1 year before index (i.e., year of symptom onset) through 10 years after index. Costs for each referent subject were subtracted from those for his/her matched case. Tests for statistical significance used Wilcoxon signed ranks. Preindex costs were similar [median difference in annual costs (MD) = -$3; P = 0.59). One year post index, PD subjects exhibited borderline significantly higher costs compared to referent subjects (MD = $581; P = 0.052); the difference diminished over 5 years (MD = $118; P = 0.82). By 5 to 10 years, however, PD subjects exhibited significantly higher costs (MD = $1,146; P = 0.01). Over the full 10 years, excess costs were concentrated among PD subjects without rest tremor (MD = $2,261, P < 0.01, for those without tremor and -$229, P = 0.99, for those with tremor). These population-based estimates of PD-associated direct medical costs from onset forward can uniquely inform policy decisions and cost-effectiveness research.

KW - Cost

KW - Cost analysis

KW - Parkinson's disease

KW - Parkinsonian disorders

KW - Utilization

UR - http://www.scopus.com/inward/record.url?scp=33845214966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845214966&partnerID=8YFLogxK

U2 - 10.1002/mds.21075

DO - 10.1002/mds.21075

M3 - Article

VL - 21

SP - 1864

EP - 1871

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 11

ER -